Specialist commentators

Advice

The following clinicians contributed to this briefing:

Thomas Wagner, consultant in nuclear medicine, Royal Free London NHS Trust, did not declare any interests.
Gary Cook, honorary consultant in nuclear medicine / professor of PET imaging, King's College London / Guy's & St Thomas' NHS Trust, was paid to provide a clinical assessment of ¹¹C‑choline scans for a study sponsored by Blue Earth Diagnostics, provided consultancy services for NanoMab Technology Ltd, was an invited member of Prostate Cancer UK (PCUK) / NHS England Cancer Diagnostics Clinical Reference Group Joint meeting on new imaging methods for detecting disseminated disease (2018), contributed to Royal College of Radiologists / Royal College of Physicians guidelines on the clinical use of PET (2013 and 2016), his department was provided with a part-salary for a clinical research fellow by Thermognostics Ltd.
Anwar R Padhani, professor of cancer imaging; consultant radiologist, lectured on Siemens Healthineers courses on the use of next generation imaging technologies for the assessment of advanced prostate cancer.
Nagabhushan Seshadri, consultant in nuclear medicine, Royal Liverpool University Hospital, did not declare any interests.
Roberto Alonzi, consultant in clinical oncology, Mount Vernon Cancer Centre, has taken part in the FALCON study evaluating the technology.
Dr Radhakrishnan Jayan, consultant in radiology and nuclear medicine, Royal Liverpool University Hospital, did not declare any interests.

Representatives from the following patient organisations contributed to this briefing: